Call Us Now : (609) 443-4500 | Easy Pay | Download New Patient Forms

Dr. Jerry Bagel is a certified dermatologist at Windsor Dermatology, and is an expert in the treatment of psoriasis.

Board Certified Dermatologist

Dr. Bagel is a nationally recognized expert in the treatment of psoriasis and is regularly invited to speak across the country and internationally about this medical condition and its treatment. Dr. Bagel has been named a Top Doctor in the Castle Connolly Medical Top Doctors of the New York Metro Area every year from 2001-2015. He was named a 2005 New Jersey Top Doctor by New Jersey Life; a Best Doctor in New Jersey by New Jersey Monthly in 2001 and 2003; and received a Patients’ Choice award in 2008 as well as in Inside Jersey in 2013 and 2015. He is a four term member of the medical advisory board of the National Psoriasis Foundation. Dr. Bagel is an Editor of Practical Dermatology and the Assistant Editor of Psoriasis Forum. He has published extensively on the topic of psoriasis in such journals as The Journal of the American Academy of Dermatology and The Journal of Drugs & Dermatology. Dr. Bagel loves spending his free time at the beach, watching the Mets and enjoying great cuisine!

Education

  • Board certified in dermatology
  • Fellow of the American Academy of Dermatology
  • Education: Bachelor of Arts, Boston University; Master of Science, Rutgers University; Doctor of Medicine, Mount Sinai School of Medicine
  • Internship in Internal medicine: University of Miami-Jackson Memorial Hospital
  • Residency in dermatology: College of Physicians and Surgeons, Columbia University
  • Practicing dermatology and dermatologic surgery for 30 years
  • Senior Attending Physician at the University Medical Center at Princeton

Publications

  • 2014 Combining Biologic Therapies With Other Systemic Treatments in Psoriasis October 2014
  • 2014 Biosimilars Journal of Drugs and Dermatology. July 2014.
  • 2014 From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. Journal of the American Academy of Dermatology 2014 Jan; 70(1):168-77
  • 2013 Clinical Study Results of Desoximetasone Spray, 0.25% In Moderate to Severe Plaque Psoriasis. Journal of the American Academy of Dermatology. 2013 Dec; 12(12):1404-10.
  • 2012 Consensus Guidelines for the Management of Plaque Psoriasis. Archives of Dermatology. 2012 Jan; 148(1):95-102.
  • 2011 Moderate to Severe Plaque Psoriasis with Scalp Involvement: A Randomized, Double-Blind, Placebo-Controlled Study of Etanercept. Journal of the American Academy of Dermatology. 2012 Jul; 67(1):86-92.
  • 2011 Adalimumab plus Narrowband Ultraviolet B Light Phototherapy for the Treatment of Moderate to Severe Psoriasis. Journal of the American Academy of Dermatology April 2011; 10(4):366-71.
  • 2011 A Review of Phototherapy Protocols for Psoriasis Treatment. Journal of the American Academy of Dermatology. May 2011; 64(5):936-49
  • 2011 Adalimumab Plus Narrowband Ultraviolet B Light Phototherapy for the Treatment of Moderate to Severe Psoriasis, Journal of Drugs in Dermatology, April 2011.
  • 2011 Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet: Efficacy and Safety Results from REACH, a Randomized, Placebo-Controlled, Double-Blind Trial. Archives of Dermatology. April 2011; 147 (4):429-36
  • 2010 Optomizing Topical Therapies for Treating Psoriasis: A Consensus Conference. Cutis, Sept. 2010
  • 2010 Treatment of Pediatric Psoriasis: Practical Dermatology, September 2010
  • 2009 Topical Therapies for the Treatment of Plaque Psoriasis: Cutaneous Medicine for the Practitioner, Vol. 84, No. 4S pgs. 3- 13, October 2009
  • 2009 Kalb, Korman et al, Treatment of intertriginous psoriasis: From the Medical Board of National Psoriasis Foundation: J Am Acad Dermatology, 2009 January; 60 (1): pgs. 120-124
  • 2009 Understanding PML and Risks Associated with Biologic Therapies: Practical Dermatology, Vol. 6, No. 5 pgs. 26-27, May 2009.
  • 2009 Treatment of Effective Therapy: Lead Psoriasis Patients along the Path to Clearance, Practical Dermatology, Vol. 6, No. 2 , pgs. 42-47, February 2009.
  • 2009 LCD plus NB-UVB reduces Time to Improvement of Psoriasis vs. NB-UVB Alone, Journal of Drugs in Dermatology, Vol. 8 Issue 4 April 2009.
  • 2009 Treatment of intertiginous psoriasis: From the Medical Board of the National Psoriasis Foundation, Journal of the American Academy of Dermatology, Vol. 60, Issue 1, January, 2009.
  • 2008 Topical Psoriasis Therapy: Patients’ Experiences, Physicians’ Perceptions Don’t Always Match, Practical Dermatology, Vol. 5, No. 2, pgs 58-61, February, 2008.
  • 2008 Utilization of Narrow-Band Ultraviolet Light B Therapy and Etanercept for the Treatment of Psoriasis (UNITE): Efficacy, Safety, and Patient-Reported Outcomes, Journal of Drugs in Dermatology, January, 2008.
  • 2008 From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis, Journal of the American Academy of Dermatology, Vol. 58, and No. 1 pgs 94-105, January, 2008.
  • 2007 Be Prepared to Treat Pustular Psoriasis—An Uncommon Variant, Practical Dermatology, Vol. 4, No. 12, pg. 43, December, 2007.
  • 2007 Choosing the Safest Psoriasis Treatment for Women of Childbearing Potential, Practical Dermatology, Vol. 4, No. 11, pg. 50-51, November, 2007.
  • 2007 Effective Strategies To Treat Intertriginous Psoriasis, Practical Dermatology, Vol. 4, No. 10, pg. 54-58, October, 2007.
  • 2007 Responding to the Potential Effects of Obesity on Psoriasis, Practical Dermatology, Vol. 4, No. 9, pg. 46-47, September, 2007.
  • 2007 Building Long-Term Relationships as a Patient Caregiver, Practical Dermatology, Vol. 4, No. 8, pg. 53-54, August, 2007.
  • 2007 Get Familiar with the Biologics Safety Dance, Practical Dermatology, Vol. 4, No. 7, pg. 17-18, July, 2007.
  • 2007 Guidelines for Use of PUVA and Tips for Success, Practical Dermatology, Vol. 4, No. 6, pg. 56-57, June, 2007.
  • 2007 Psoriasis Research You and Your Patients Can Take to the Bank, Practical Dermatology, Vol. 4, No. 5, pg. 56-58, May, 2007.
  • 2007 Exploring Off-Label Use of Biologics for Dermatologic Indications, Practical Dermatology, Vol.4, No.5, pg.56-58. April, 2007.
  • 2007 Assessment and tracking of long-term alefacept safety, Journal of the American Academy of Dermatology, Vol.56, Issue 2, Supplement2, February, 2007.
  • 2007 National Psoriasis Foundation Clinical Consensus on Disease Severity, Archives of Dermatology, Vol. 143, February, 2007.
  • 2007 Evaluating the Risks and Benefits of Soriatane, Practical Dermatology, Vol. 4, No. 2, pg. 82-84, February, 2007.
  • 2007 New Perspectives on Methotrexate and Liver Biopsies, Practical Dermatology, Vol. 4, No. 1, pg. 74-75, January, 2007.
  • 2006 How and When to Use Cyclosporine in Psoriasis Care, Practical Dermatology, Vol..3, No. 12. pg. 58-61, December, 2006.
  • 2006 Practical Dermatology: In the Pipeline: Promising Early Data for a New Biologic. November, 2006: 3:11 pg. .25-26.
  • 2006 Practical Dermatology: Approaches to Difficult-to- Treat Psoriasis in Specialized Areas. October, 2006: 3:10 pg 48-50.
  • 2006 Journal of Drugs in Dermatology, Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study
  • 2006 Unlock the Benefits of Phototherapy for Psoriasis: Practical Dermatology, April, 2006: pg. 41
  • 2005 Psoriasis Combination Therapy: Psoriasis Forum
  • 2005 Decision points for the initiation of systemic treatment for psoriasis: Journal of the American Academy of Dermatology, 53:101, 2005
  • 2005 Chordoma Cutis: Journal of the American Academy of Dermatology, 52:S105, 2005
  • 2003 Lowe NJ, Gonzalez J., Bagel, J. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003;42:224-230.
  • 2002 A guide to Introducing Biologic Therapies for Psoriasis into Clinical Practice: Precept Medical Communications
  • 2001 Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes: New England Journal of Medicine, 345:248, 2001
  • 2000 Establishing a Practical and Effective Psoriasis Treatment Center: Dermatologic Clinics of North America, April, 2000
  • 1998 Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial; Journal of American Academy of Dermatology, 38:938, 1998
  • 1985 Subcutaneous Nodules in Pseudomas Septicemia; American Journal of Medicine, 80:528, 1986
  • 1985 Hemorrhagic Bullae Associated with Morganella Morganii Septicemia; Journal of the American Academy of Dermatology, 12:575, 1985
  • 1985 Wavelength Dependence for 4’, 5’ – Monoadduct Formulation in UVA Irradiated 8-Methoxypsoralen and Calf Thymus DNA; Photochemistry and Photobiology, 42:95, 1985

 

Jerry Bagel: Addressing Comorbidities in Plaque Psoriasis

Read full article here >>

Jerry Bagel, MD: Starting the Treatment Process for Plaque Psoriasis

Read full article here >>

Jerry Bagel: Approaching Psoriasis Treatment Based on Location

Read full article here >>

Jerry Bagel, MD: Evolution of Psoriasis Treatment Means Better Results for Patients

Read full article here >>

Research in Eczema Is Lacking, Despite Progress in Psoriasis

Read full article here >>

Jerry Bagel, MD, from the Psoriasis Treatment Center of Central New Jersey: Moving Beyond Tar and Lights in Treatment of Plaque Psoriasis

Read full article here >>

Jerry Bagel, MD, Explains How to Measure Success in Psoriasis Treatment

Read full article here >>